Activating ESR1 mutations in hormone-resistant metastatic breast cancer

[1]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[2]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[3]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[4]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[5]  P. Lønning,et al.  Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved , 2013, Endocrine-related cancer.

[6]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[7]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[9]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[10]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[11]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[12]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[13]  Todd R. Golub,et al.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.

[14]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[15]  Arul M Chinnaiyan,et al.  Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. , 2011, Neoplasia.

[16]  S. Salzberg,et al.  TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.

[17]  Stephen L. Abrams,et al.  Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy , 2011, Oncotarget.

[18]  Ken Chen,et al.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.

[19]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[20]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[21]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[22]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[23]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[24]  S. Fuqua,et al.  Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling , 2010, Clinical Cancer Research.

[25]  M. Ellis,et al.  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.

[26]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[27]  V. Jordan,et al.  Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. , 2008, Clinical breast cancer.

[28]  R. Riggins,et al.  Pathways to tamoxifen resistance. , 2007, Cancer letters.

[29]  D. F. Skafar.  Formation of a powerful capping motif corresponding to start of “helix 12” in agonist-bound estrogen receptor-α contributes to increased constitutive activity of the protein , 2007, Cell Biochemistry and Biophysics.

[30]  E. Perez,et al.  Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Ariazi,et al.  Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.

[32]  A. Koide,et al.  Mutation of Leu-536 in Human Estrogen Receptor-α Alters the Coupling between Ligand Binding, Transcription Activation, and Receptor Conformation* , 2003, Journal of Biological Chemistry.

[33]  Hong Liu,et al.  Modulation of Estrogen Receptor α Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12* , 2003, The Journal of Biological Chemistry.

[34]  D. McDonnell,et al.  Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. , 2002, Molecular endocrinology.

[35]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[36]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[37]  K E Carlson,et al.  Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. , 1997, Biochemistry.

[38]  P Chambon,et al.  Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. , 1997, Biochemical and biophysical research communications.

[39]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[40]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[41]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.